4-(苯甲基氨酰基)苯硼酸频哪酯 | 1073353-57-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(苯甲基氨酰基)苯硼酸频哪酯
• 中文别名: 4-(N-苄基氨基羰基)苯基硼酸频哪醇酯；4-(N-苄基氨基羰基)苯硼酸频那醇酯；4-(苯甲基氨酰基)苯硼酸频哪酯,97%
• 英文名称: N-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
• CAS: 1073353-57-7
• 化学式: C₂₀H₂₄BNO₃
• mdl: MFCD09266184
• 分子量: 337.226
• InChiKey: VAFYISMQZLEYKR-UHFFFAOYSA-N

物化性质

• 熔点：
  109-113°C
• 沸点：
  511.1±43.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.57
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(N-Benzylaminocarbonyl)phenylboronic acid, pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(N-Benzylaminocarbonyl)phenylboronic acid, pinacol ester
CAS number: 1073353-57-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C20H24BNO3
Molecular weight: 337.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(苯甲基氨酰基)苯硼酸频哪酯 在 N-溴代丁二酰亚胺(NBS) 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  发现4,7-二氨基-5-（4-苯氧基苯基）-6-亚甲基-嘧啶[5,4- b ]吡咯烷酮作为新型布鲁顿酪氨酸激酶抑制剂

  摘要：

  通过将吡唑并[3,4- d ]嘧啶组分合并成三环骨架，对布鲁顿酪氨酸激酶（BTK）抑制剂1（依鲁替尼）进行了另一种药物化学处理。制备了两种类型的化合物，并确定了它们对BTK的生化活性以及立体化学作用。进行了结构优化，重点是与BTK Cys481的反应性结合基团和以代谢研究为指导的代谢位点。7S被认为是最有效的，对BTK的IC 50值为0.4 nM，对BTK依赖的TMD8细胞的IC 50为16 nM。相比1，7S对B细胞受体信号通路的抑制作用强一些。在源自TMD8细胞的动物异种移植模型中，7S在15 mg / kg QD剂量下显示出5.3的相对肿瘤体积，在25 mg / kg QD较高剂量下比1（RTV 6.6）更有效。所有这些结果表明7S是一种值得进一步分析的新型BTK抑制剂。

  DOI：

  10.1021/acs.jmedchem.8b00441
• 作为产物：
  描述：

  4-羧基苯硼酸 在 1-羟基苯并三唑 、 三乙胺 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 52.0h， 生成 4-(苯甲基氨酰基)苯硼酸频哪酯
  参考文献：
  名称：

  Identification of new γ-hydroxybutenolides that preferentially inhibit the activity of mPGES-1

  摘要：

  Microsomal prostaglandin E-2 synthase-1 (mPGES-1) has been recognized as novel, promising drug target for anti-inflammatory and anticancer drugs. mPGES-1 catalyzes the synthesis of the inducible prostaglandin E-2 in response to pro-inflammatory stimuli, rendering this enzyme extremely interesting in drug discovery process owing to the drastic reduction of the severe side effects typical for traditional non-steroidal anti-inflammatory drugs. In the course of our investigations focused on this topic, we identified two interesting molecules bearing the gamma-hydroxybutenolide scaffold which potently inhibit the activity of mPGES-1. Notably, the lead compound 2c that inhibited mPGES-1 with IC50 = 0.9 mu M, did not affect other related enzymes within the arachidonic acid cascade. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.06.032

文献信息

• C(sp ³ )–H methylation enabled by peroxide photosensitization and Ni-mediated radical coupling
  作者：Aristidis Vasilopoulos、Shane W. Krska、Shannon S. Stahl

  DOI：10.1126/science.abh2623

  日期：2021.4.23

  candidate associated with addition of a single methyl group. We report a synthetic method that enables direct methylation of C(sp3)–H bonds in diverse drug-like molecules and pharmaceutical building blocks. Visible light–initiated triplet energy transfer promotes homolysis of the O–O bond in di-tert-butyl or dicumyl peroxide under mild conditions. The resulting alkoxyl radicals undergo divergent reactivity

  “神奇甲基”效应描述了与添加单个甲基相关的候选药物的效力、选择性和/或代谢稳定性的变化。我们报告了一种合成方法，可以直接甲基化各种药物样分子和药物构件中的 C(sp 3 )–H 键。在温和条件下，可见光引发的三重态能量转移促进二叔丁基或过氧化二异丙苯中O-O键的均裂。产生的烷氧基自由基经历不同的反应性，要么从底物 C-H 键进行氢原子转移，要么通过 β-甲基断裂生成甲基自由基。这些步骤的相对速率可以通过改变反应条件或过氧化物取代基来调节，以优化由镍介导的底物和甲基自由基的交叉偶联产生的甲基化产物的产率。
• Aminoheteroaryl benzamides as kinase inhibitors
  申请人：Bagdanoff Jeffrey T.

  公开号：US09242996B2

  公开（公告）日：2016-01-26

  The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

  本发明提供了化合物的化合物（I）或其盐； 以及这些化合物的治疗用途。本发明还提供了包含这些化合物的药物组合物，以及包含这些化合物与治疗辅助剂的组合物。
• Hydrogen Bond Directed <i>ortho</i> ‐Selective C−H Borylation of Secondary Aromatic Amides
  作者：Shao‐Tao Bai、Charles B. Bheeter、Joost N. H. Reek

  DOI：10.1002/anie.201907366

  日期：2019.9.9

  iridium catalyst for ortho‐selective C−H borylation of challenging secondary aromatic amide substrates, and the regioselectivity is controlled by hydrogen‐bond interactions. The BAIPy‐Ir catalyst forms three hydrogen bonds with the substrate during the crucial activation step, and allows ortho‐C−H borylation with high selectivity. The catalyst displays unprecedented ortho selectivities for a wide variety

  据报道是一种铱催化剂，可用于具有挑战性的二级芳族酰胺底物的邻位选择性CH硼化，其区域选择性受氢键相互作用的控制。所述BAIPy -Ir催化剂在至关重要的激活步骤形成与所述衬底三个氢键，并且允许邻-C-H硼化高选择性。该催化剂 对电子和空间特性不同的多种底物显示出空前的邻位选择性，并且该催化剂可耐受各种官能团。区域选择性CH硼化催化剂易于获得，并以高选择性和高转化率以克为单位转化底物。
• Arylboronic acids as dual-action FAAH and TRPV1 ligands
  作者：Enrico Morera、Vincenzo Di Marzo、Ludovica Monti、Marco Allarà、Aniello Schiano Moriello、Marianna Nalli、Giorgio Ortar、Luciano De Petrocellis

  DOI：10.1016/j.bmcl.2016.01.071

  日期：2016.3

  A series of 31 arylboronic acids designed on the basis of the pharmacophore model for a variety of TRPV1 antagonists was prepared and tested on FAAH and TRPV1 channel. Four of them, that is, compounds 3c, 4a, 5a,b acted as dual FAAH/TRPV1 blockers with IC50 values between 0.56 and 8.11 μM whereas ten others (compounds 1c,f–i, 2c–f, 4b) inhibited FAAH and activated/desensitized TRPV1.

  制备了一系列基于药效团模型设计的31种芳基硼酸，用于各种TRPV1拮抗剂，并在FAAH和TRPV1通道上进行了测试。其中四个化合物，即化合物3c，4a，5a，b充当双重FAAH / TRPV1阻滞剂，IC 50值在0.56至8.11μM之间，而其他十种化合物（化合物1c，f – i，2c – f，4b）则抑制FAAH和激活/脱敏的TRPV1。
• AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS
  申请人：BAGDANOFF Jeffrey T.

  公开号：US20150126490A1

  公开（公告）日：2015-05-07

  The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

  本发明提供了公式(I)的化合物或其盐；以及这些化合物的治疗用途。本发明还提供了包含这些化合物的制药组合物，以及包含这些化合物和治疗协同剂的组合物。